Advanced searches left 3/3

Metronomic therapy - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 23 June 2022

* If you want to update the article please login/register

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors

Arm A: Nivolumab + Cyclophosphamide-Vinblastine Arm B: Arm B: Nivolumab + Capcitabin Arm B: Arm A: Nivolumab + Cyclophosphamide-Vinblastine Arms: Arm A: Nivolumab+Capt. 1: Arm B: Nivolumab + Cyclophosphamide-Vinblastine Arm B: Arm A: Arm B: Arm A: Arm A: Arm A: Arm A: Arm B: Arm A: Arm A: Arm A: Arm A: Arm B: Arm A: Arm A: Arm A: Arm C: Arm A: B: Nivolumab + Arm A: B: Arm B + Arm A: Nivolumab + Arm A: Nivolumab + Arm B /Arm C: Nivolumab + Arm B: B + Nivolumab + Capecitabinblastine Arm B: Nivolumab + Arm B + Capecitabinblastine Arm B: Arm B: Arm B + Nivolumab + Arm C Arm C has been activated, after arm A and Arm B were deemed safe. Trans-MetroPD1 is divided into three axes: to assess the health-related quality of life to determine the expression of immune cells within blood cells to determine the distribution of immune cells within blood tissue; and to determine the distribution of immune cells within blood cells.

Source link: https://clinicaltrials.gov/ct2/show/NCT03585465

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

Source Recommendations

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions